Actively Recruiting
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Led by National Cancer Institute (NCI) · Updated on 2026-05-13
26
Participants Needed
14
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma.
CONDITIONS
Official Title
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of multiple myeloma according to international criteria
- If previously had autologous stem cell transplant, it must have been more than 100 days ago
- Disease has progressed after at least 4 prior anti-myeloma treatments including one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 monoclonal antibody
- Measurable disease by specific protein levels in blood or urine; non-secretory disease patients allowed
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 (Karnofsky score 60 or higher)
- Hemoglobin, neutrophil count, platelets, liver enzymes, kidney function, and urine protein levels within defined limits
- HIV patients on effective therapy with undetectable viral load within 6 months are eligible
- Patients with controlled hepatitis B or cured hepatitis C are eligible
- Patients with treated or stable brain metastases may participate
- Prior or concurrent cancers allowed if not interfering with study
- Cardiac function assessed as New York Heart Association class II or better
- Females of childbearing potential must use effective contraception and have negative pregnancy tests before and during treatment
- Men must agree to contraception and abstain from donating sperm during and after treatment
- Agree to not donate blood during and after treatment
- Ability to understand and sign informed consent
- Willingness to comply with study visits and provide required samples
- Willingness to return for follow-up visits
You will not qualify if you...
- Active plasma cell leukemia, AL amyloidosis, POEMS syndrome, or Waldenstrom macroglobulinemia
- Prior treatment with anti-BCMA bispecific antibodies or cereblon E3 ligase modulators including iberdomide
- Received plasmapheresis within 7 days before study
- Prior allogeneic stem cell transplant (autologous allowed)
- Received live vaccines within 30 days before study (COVID-19 vaccine allowed anytime)
- Active infections requiring treatment
- Unresolved side effects from prior treatment greater than grade 2, except alopecia or mild neuropathy
- Major surgery within 4 weeks before study
- Uncontrolled illness or conditions making study participation unsafe
- Active mucosal or internal bleeding
- Unstable liver or biliary disease, except stable chronic liver disease
- Known allergies to teclistamab, iberdomide, or study components
- Currently on anticancer therapies other than allowed hormonal or limited radiotherapy
- Need for high-dose immunosuppressive medications
- Use of strong CYP3A4/5 inhibitors or inducers
- Receiving other investigational treatments
- Pregnant or breastfeeding women
- Unable or unwilling to use blood clot prevention measures required by the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States, 85054
Actively Recruiting
2
Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut, United States, 06418
Actively Recruiting
3
Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut, United States, 06437
Actively Recruiting
4
Yale University
New Haven, Connecticut, United States, 06520
Actively Recruiting
5
Yale-New Haven Hospital North Haven Medical Center
North Haven, Connecticut, United States, 06473
Actively Recruiting
6
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224-9980
Actively Recruiting
7
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Suspended
8
University of Kansas Cancer Center
Kansas City, Kansas, United States, 66160
Actively Recruiting
9
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, United States, 66210
Actively Recruiting
10
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States, 66205
Actively Recruiting
11
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
12
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Actively Recruiting
13
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
14
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, United States, 23298
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here